6533b827fe1ef96bd1286498

RESEARCH PRODUCT

Peut-on proposer un prélèvement du ganglion sentinelle en cas de chimiothérapie néoadjuvante dans les cancers du sein et à quel moment ?

Charles CoutantH. PorthaClémentine JankowskiEmmanuel Barranger

subject

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrySentinel lymph nodeObstetrics and GynecologyAxillary Node DissectionGeneral Medicine030230 surgerySentinel nodemedicine.disease3. Good health03 medical and health sciences0302 clinical medicineBreast cancerReproductive MedicineNeoadjuvant treatment030220 oncology & carcinogenesisCytologyBiopsyMedicinePreoperative chemotherapyRadiologybusiness

description

The main goal of preoperative chemotherapy is to reduce the size of the tumor and allow conservative treatment. Neoadjuvant treatment can affect axillary status with a downstaging in one third of the cases. For these patients, the benefit of axillary node dissection is questioned and the sentinel node biopsy (SLNB) seems to be a relevant option. However, the timing of performing SLNB is still debated especially for clinical negative patients with negative axillary ultrasound before preoperative chemotherapy. For axillary positive nodes proved by biopsy/cytology before preoperative chemotherapy, SLNB can be an option if there is a good clinical and radiological response.

https://doi.org/10.1016/j.gyobfe.2016.04.010